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Challenging Achievement of Bidirectional Block After Linear Ablation
Affects the Rhythm Outcome in Patients With Persistent Atrial
Fibrillation
Tae-Hoon Kim, MD; Junbeom Park, MD, PhD; Jae-Sun Uhm, MD, PhD; Jong-Youn Kim, MD, PhD; Boyoung Joung, MD, PhD;
Moon-Hyoung Lee, MD, PhD; Hui-Nam Pak, MD, PhD
Background-—It is not clear whether bidirectional block (BDB) of linear ablations reduces atrial ﬁbrillation (AF) recurrence after
radiofrequency catheter ablation. We hypothesized that BDB of linear ablation has prognostic signiﬁcance after radiofrequency
catheter ablation for persistent AF.
Methods and Results-—Among 1793 consecutive patients in the Yonsei AF ablation cohort, this observational cohort study
included 398 patients with persistent AF (75.6% male; age, 59.810.3 years) who underwent catheter ablation with a consistent
ablation protocol of the Dallas lesion set: circumferential pulmonary vein isolation; cavotricuspid isthmus ablation (CTI); roof line
(RL); posterior-inferior line (PIL); and anterior line (AL). BDB rates of de novo ablation lines were 100% in circumferential pulmonary
vein isolation, 100% in CTI, 84.7% in RL, 44.7% in PIL, and 63.6% in AL. During 29.018.4 months of follow-up, 31.7% (126/398) of
the patients showed clinical recurrence. Left atrial posterior wall (LAPW) isolation (BDBs of RL and PIL) was independently
associated with lower clinical AF/atrial tachycardia recurrence (hazard ratio, 0.68; 95% CI, 0.47–0.98; P=0.041; log-rank,
P=0.017), whereas BDBs of RL or AL were not (log-rank, P=0.178 for RL; P=0.764 for AL). Among 52 patients who underwent
repeat procedures (23.016.1 months after de novo procedure), the BDB maintenance rates for CTI, RL, PIL, and AL were 94.2%
(49 of 52), 63.5% (33 of 47), 62.1% (18 of 29), and 61.8% (21 of 34), respectively.
Conclusions-—Although PIL crosses the esophageal contact area, LAPW isolation is important for better clinical outcome in
catheter ablation with a linear ablation strategy for patients with persistent AF. ( J Am Heart Assoc. 2016;5: e003894 doi:
10.1161/JAHA.116.003894)
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C atheter ablation is an established treatment modality forpatients with paroxysmal atrial ﬁbrillation (AF),1 and
circumferential pulmonary vein isolation (CPVI) is the corner-
stone technique of AF catheter ablation.2 However, in
persistent AF (PeAF), non-pulmonary-vein (PV) triggers play
important roles in the pathophysiology and CPVI alone
generally does not achieve a satisfactory clinical outcome.3
Therefore, many additional substrate modiﬁcation strategies
have been proposed for PeAF ablation. One of the most widely
used strategies is additional linear ablation in conjunction
with CPVI4,5; however, the beneﬁt of additional linear lesions
remains controversial. Although many previous studies have
demonstrated an incremental beneﬁt of additional linear
ablation post-CPVI,4–8 linear ablation can be technically
challenging to achieve bidirectional block (BDB), may be
proarrhythmic if it is incomplete, and has a risk of compli-
cations.9 A recent large, randomized, controlled trial, STAR AF
II, showed no incremental beneﬁt of additional linear ablation
with a 74% BDB rate of additional linear lesions.10 Because it
is not clear whether completeness of linear ablations
inﬂuences the clinical outcome of catheter ablation, we
hypothesized that BDB of linear ablation has prognostic
signiﬁcance after catheter ablation for persistent AF. The
aims of this study were to (1) characterize the rate of
achievement of complete BDB for each linear ablation lesion and
durability of BDB at repeat procedures, (2) explore predictors for
BDB achievement, and (3) investigate the prognostic value of
complete BDB of each linear lesion after the procedure among
patients with persistent AF who underwent catheter ablation.
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The study protocol adhered to the principles of the Declara-
tion of Helsinki and was approved by the Institutional Review
Board at Yonsei University Health System. All patients
provided written informed consent for inclusion in the Yonsei
AF Ablation Cohort Database (ClinicalTrials.gov Identiﬁer:
NCT02138695). Among 1793 patients with AF who under-
went catheter ablation, the study population included 398
patients with PeAF (75.6% male; age, 59.810.3 years) who
underwent a catheter ablation procedure with a consistent
ablation protocol of the Dallas lesion set: CPVI; cavotricuspid
isthmus (CTI) ablation; posterior wall box lesion (roof line [RL]
and posterior inferior line [PIL]); and anterior line (AL).6
Exclusion criteria were as follows: (1) permanent AF refractory
to electrical cardioversion; (2) AF with valvular disease >grade
2; (3) any form of cardiomyopathy with uncontrolled heart
failure or a left ventricular ejection fraction of <45%; (4)
congenital heart disease; (5) history of cardiac surgery; and
(6) previous ablation procedure. Before all ablation proce-
dures, the anatomy of the LA and PV was visually deﬁned on
three-dimensional (3D) computed tomography (CT) scans (64
Channel, Light Speed Volume CT; Brilliance 63; Philips, Best,
The Netherlands). All antiarrhythmic drugs were discontinued
for a period of at least 5 half-lives, and amiodarone was
stopped at least 4 weeks before the procedure.
Electrophysiological Mapping
Intracardiac electrograms were recorded using the Prucka
CardioLab Electrophysiology system (General Electric Medical
Systems, Inc., Milwaukee, WI), and radiofrequency (RF)
catheter ablation (RFCA) was performed in all patients using
3D electroanatomical mapping (NavX, St. Jude Medical, Inc.,
Minnetonka, MN) merged with 3D spiral CT. Double trans-
septal punctures were made and multiview pulmonary
venograms were obtained. After securing trans-septal access,
a circumferential PV-mapping catheter (Lasso; Biosense-
Webster Inc., Diamond Bar, CA) was introduced with a long
sheath (Schwartz left 1; St. Jude Medical). Systemic antico-
agulation was performed with intravenous heparin to maintain
an activated clotting time of 350 to 400 seconds during the
procedure. For electroanatomical mapping, 3D geometry of
both the left atrium (LA) and PV was generated using the NavX
system and then merged with 3D spiral CT images.
RFCA
Details of the RFCA technique and strategy used in our center
are described in our previous study.11 Brieﬂy, we used an
open irrigated-tip catheter (Coolﬂex; 25–35 W, irrigation rate
of 10–15 mL/min; St. Jude Medical) to deliver RF energy for
ablation. All patients initially underwent CPVI and CTI ablation.
RL, PIL, and AL6 were added as the standard lesion set, also
known as the “Dallas lesion set” (Figure 1A). To generate the
posterior box lesion, linear ablations of RL and PIL were made
by connecting both sides of the CPVI at the top and bottom
levels, respectively. AL was generated by ablation from the
mitral annulus at the 12 o’clock position toward the LA RL.6 If
atrial tachyarrhythmias could not be terminated by standard
lesion set ablation, internal cardioversion and evaluation of
BDB state were performed. BDB of RL was conﬁrmed by
differential pacing from LA appendage versus LA posterior









Figure 1. A, Catheter Dallas lesion ablation set with electroanatomical activation map acquired during stable right atrial pacing revealing
LAPW isolation without AL block. B, The same patient recurred as atrial tachycardia, and the redo mapping (activation map) 32 months after the
index procedure shows focal tachycardia originated from LAPW and conducted to the anterior portion of LA through the reconnected RL. AL
indicates anterior line; AT, atrial tachycardia; LAPW, left atrial posterior wall; RL, roof line.
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wall (LAPW) and successful generation of PIL was considered
to be achievement of LAPW isolation, which was deﬁned as no
endocardial electrogram in the LAPW with a setting of RL
block and no capture of isolated LAPW pacing (Figure 1A).
BDB of AL was conﬁrmed by differential pacing from LA
appendage versus LA septum.6 When BDB of linear ablation
lines was not achieved, additional ablations were performed
to achieve BDB of these lines. However, if BDB could not be
achieved after 3 attempts of linear ablation, those lines were
kept unblocked to avoid collateral damage. The operators
could opt to perform additional ablations in the superior vena
cava or non-PV foci, or conduct complex fractionated
electrograms12 at their discretion. If there were mappable
AF triggers or atrial premature beats with isoproterenol
infusion (5 lg/min), we carefully mapped and ablated those
non-PV foci as much as possible. All RFCA procedures were
conducted according to the above speciﬁc protocol by 2
operators with more than 10 years of experience.
Postablation Management and Follow-up
Among 398 patients, 95 (23.9%) maintained antiarrhythmic
medication before AF recurrence because of a high chance of
recurrence with frequent atrial premature beats or short runs
of nonsustained atrial tachycardia (AT). Patients visited the
outpatient clinic regularly at 1, 3, 6, and 12 months post-
RFCA and then every 6 months thereafter or whenever they
experienced symptoms. All patients underwent electrocardio-
graphy (ECG) during every visit and 24-hour Holter recording
at 3 and 6 months and then every 6 months, in accord with
the 2012 HRS/EHRA/ECAS Expert Consensus Statement
guidelines.13 However, patients reporting symptoms of palpi-
tations underwent Holter monitor or event monitor recordings
and were evaluated for the possibility of arrhythmia recur-
rence. The primary endpoint was the clinical recurrence of
atrial tachyarrhythmia as any episode of AF or AT lasting for at
least 30 seconds in duration.13 Any ECG documentation of
AF/AT recurrence after 3 months of the blanking period was
diagnosed as clinical recurrence.13 However, AF/AT recur-
rence in the ﬁrst 3 months after catheter ablation (blanking
period) was counted as early recurrence. Early recurrence was
neither classiﬁed as clinical AF/AT recurrence nor used in all
data analyses.
Statistical Analysis
Statistical analysis was performed using SPSS (Statistical
Package for Social Sciences, Chicago, IL) software for
Windows (version 20.0). Continuous variables were expressed
as mean SD and were compared using the Student t test.
Categorical variables were reported as frequency (percentage)
and compared using chi-square test and Fisher’s exact test.
Kaplan–Meier analyses with log-rank tests were used to
calculate AF recurrence-free survival over time and compare
recurrence rates across groups. Logistic regression analyses
were used to identify predictors of LAPW isolation, and Cox
regression analyses were used to assess independent
predictors of AF and/or AT recurrence after RFCA. Age, sex,
and all other variables with P value of less than 0.1 in the
univariate analyses were selected for the multivariate analy-
ses. Once AF/AT recurrence was documented by ECG after
3 months of blanking period, we considered those patients as
clinical recurrence of AT/AF. Therefore, the repeated mea-
surements of ECG or Holter recording after clinical recurrence
event were not used in statistical analyses. The duration
between catheter ablation and ﬁrst documentation of AF/AT
recurrence after 3 months of blanking period was calculated
as month and used in Kaplan–Meier analysis and Cox-




Baseline characteristics of overall study population with
respect to the presence or absence of clinical AF/AT
recurrence are shown in Table 1. There were no differences
in baseline characteristics between patients with clinical AF/
AT recurrence and those without.
Table 2 summarizes the procedural characteristics. In 398
patients with PeAF who achieved 100% CPVI, BDB rates of
additional linear ablations were 100% in CTI, 84.7% in RL, 44.7%
in PIL (conﬁrmed by LAPW isolation in patients with BDB of RL),
and 63.6% in AL. LAPW isolation has a same meaning to
achievement of both RL and PIL blocks, and no patient showed
PIL blockwithout RL block. Therewere no differences in the rate
of achievement of BDBs for CTI, RL, PIL, and AL between
patients with clinical recurrence and those without. Patients
with clinical AF/AT recurrence showed longer total procedural
time than those without clinical AF/AT recurrence
(234.6756.21 vs 210.7047.86 minutes; P<0.001), but
no difference in ablation time (6424.691594.93 vs
6345.241217.80 seconds; P=0.586).
Predictors of Successful BDB of Additional Lines
Table 3 shows logistic regression analysis of predictors for
successful BDB of additional linear ablation lines. There were
no signiﬁcant predictors for BDB achievement of RL and PIL.
Older age (odds ratio [OR], 1.03; 95% CI, 1.01–1.05; P=0.016)
and greater LA dimension in echocardiography (OR, 1.04; 95%
CI, 1.01–1.08; P=0.025) were independently associated with
BDB of AL.
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Achievement of BDB for Additional Lines and
Clinical Outcome
During 29.018.4 months of follow-up, 126 of 398 patients
(31.7%) experienced clinical AF/AT recurrence. Kaplan–Meier
analysis according to BDB of RL (log-rank, P=0.178; Fig-
ure 2A) or AL (log-rank, P=0.764; Figure 2C) showed no
signiﬁcant beneﬁt for clinical outcome after catheter ablation.
However, patients with LAPW isolation showed a signiﬁcantly
lower clinical recurrence rate compared with those without
LAPW isolation (log-rank, P=0.017; Figure 2B). Patients with a
larger number of BDB-achieving linear ablation lines showed
no signiﬁcant beneﬁt compared with those with fewer BDB-
achieving linear lines (2–3 vs 0–1; log-rank, P=0.073;
Figure 2D). In multivariate Cox regression analysis, achieve-
ment of LAPW isolation was independently associated with
lower clinical recurrence of AF/AT after catheter ablation
Table 1. Clinical and Echocardiographic Parameters According to Clinical AF/AT Recurrence
All Subjects (n=398) Clinical AF/AT Recurrence () (n=272) Clinical AF/AT Recurrence (+) (n=126) P Value
Age, y 59.8110.30 59.8410.83 59.749.09 0.928
Male sex, n (%) 301 (75.6) 203 (74.6) 98 (77.8) 0.497
Body mass index, kg/m2 25.092.83 24.972.74 25.343.00 0.227
Body surface area, m2 1.820.18 1.810.18 1.830.17 0.224
CHA2DS2-VASc score 2.011.73 2.041.82 1.931.51 0.536
CHF, n (%) 54 (13.6) 41 (15.1) 13 (10.3) 0.197
Hypertension, n (%) 218 (54.8) 147 (54.0) 71 (56.3) 0.667
Diabetes mellitus, n (%) 69 (17.4) 46 (16.9) 23 (18.4) 0.716
Stroke/TIA, n (%) 65 (16.3) 46 (16.9) 19 (15.1) 0.646
Vascular disease, n (%) 67 (16.8) 43 (15.8) 24 (19.0) 0.422
AAD at discharge, n (%) 95 (23.9) 59 (21.7) 36 (28.6) 0.134
TTE
LA dimension, mm 44.245.81 44.136.03 44.485.34 0.576
LA volume index, mL/m2 42.2012.73 42.0213.65 42.6010.50 0.682
LV mass index, g/m2 97.2024.43 97.2624.79 97.0823.73 0.950
LVEF, % 61.179.41 61.149.89 61.228.31 0.935
LVEDD 50.514.95 50.484.97 50.574.91 0.862
E/Em 10.784.22 10.954.31 10.414.00 0.224
Values are expressed as n (%) or meanSD. Any AF/AT recurrence in the ﬁrst 3 months (blanking period) after catheter ablation was not counted as clinical AF/AT recurrence. AAD
indicates antiarrhythmic drug; AF, atrial ﬁbrillation; AT, atrial tachycardia; CHF, congestive heart failure; E/Em, the ratio of early diastolic mitral inﬂow velocity (E) to early diastolic mitral
annular velocity (Em); LA, left atrium; LV, left ventricle; LVEDD, LV end diastolic dimension; LVEF, LV ejection fraction; LVMI, LV mass index; TIA, transient ischemic attack; TTE,
transthoracic echocardiography.






Recurrence (+) (n=126) P Value
Total procedure time, minute 218.3151.80 210.7047.86 234.6756.21 <0.001*
Ablation time, second 6370.321346.72 6345.241217.80 6424.691594.93 0.586
Achievement of BDB (%)
Cavotricuspid isthmus line 398 (100) 272 (100) 126 (100) —
Roof line† 337 (84.7) 236 (86.8) 101 (80.2) 0.089
Posterior-inferior line (LAPW isolation)† 178 (44.7) 130 (47.8) 48 (38.1) 0.070
Anterior line 253 (63.6) 178 (65.4) 75 (59.5) 0.254
Values are expressed as n (%) or meanSD. AF indicates atrial ﬁbrillation; AT, atrial tachycardia; BDB, bidirectional block; LAPW, left atrial posterior wall.
*P<0.05.
†
BDB of lines in 2 patients was not conﬁrmed and was counted as no achievement of bidirectional block.
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(hazard ratio [HR], 0.68; 95% CI, 0.47–0.98; P=0.041;
Table 4).
Maintenance of Bidirectional Blocks of Additional
Lines in Redo Procedures
Among 126 patients with AF recurrence, 52 (41.3%) under-
went repeat procedures at 23.0216.05 months after the de
novo procedure. Achievement rates of LAPW isolation and
BDB for linear lines at de novo procedure, redo mapping, and
postrepeat ablation are presented in Figure 3, respectively.
BDB rates for CTI, RL, LAPW, and AL were 100%, 90.4%,
55.8%, and 65.4% at the de novo procedure, and 94.2%,
63.5%, 34.6%, and 40.4% at the redo mapping, respectively;
thus, the BDB maintenance rates for CTI, RL, PIL, and AL were
94.2% (49 of 52), 63.5% (33 of 47), 62.1% (18 of 29), and
61.8% (21 of 34), respectively. After redo procedures, BDB
was ﬁnally achieved in 100% for CTI, 94.2% for RL, 65.4% for
PIL, and 76.9% for AL (Figure 3A). Among patients who
achieved LAPW isolation at the de novo procedure (n=29),
Table 3. Logistic Regression Analysis of Clinical Variables Predictive of Bidirectional Block
Univariate Analysis Multivariate Analysis
OR (95% CI) P Value OR (95% CI) P Value
Roof line
Male 0.73 (0.37–1.43) 0.354 1.18 (0.48–2.57) 0.795
Age 1.04 (1.01–1.06) 0.008 1.03 (1.00–1.06) 0.053
Body mass index, kg/m2 0.94 (0.85–1.03) 0.174
Body surface area, m2 0.21 (0.05–0.96) 0.044 0.40 (0.06–2.92) 0.369
Hypertension 1.30 (0.76–2.25) 0.341
Diabetes mellitus 1.71 (0.74–3.93) 0.209
LA dimension, mm 1.01 (0.96–1.06) 0.784
Ablation time, second 1.00 (1.00–1.00) 0.889
Procedure time, minute 1.00 (0.99–1.00) 0.066 1.00 (0.99–1.00) 0.113
Posterior-inferior line
Male 0.62 (0.39–0.99) 0.044 0.75 (0.42–1.33) 0.321
Age 1.01 (0.99–1.03) 0.580 1.00 (0.98–1.03) 0.782
Body mass index, kg/m2 0.96 (0.90–1.03) 0.276
Body surface area, m2 0.29 (0.09–0.89) 0.030 0.67 (0.14–3.17) 0.618
Hypertension 1.11 (075–1.65) 0.612
Diabetes mellitus 1.08 (0.64–1.82) 0.777
LA dimension, mm 0.96 (0.93–1.00) 0.026 0.97 (0.93–1.01) 0.095
Ablation time, minute 0.99 (0.98–1.00) 0.035 0.99 (0.98–1.00) 0.135
Procedure time, minute 1.00 (0.99–1.00) 0.126
Anterior line
Male 0.77 (0.47–1.25) 0.293 0.81 (0.49–1.34) 0.407
Age 1.03 (1.01–1.05) 0.007 1.03 (1.01–1.05) 0.016*
Body mass index, kg/m2 0.98 (0.92–1.06) 0.669
Body surface area, m2 0.48 (0.15–1.51) 0.209
Hypertension 1.38 (0.92–2.09) 0.121
Diabetes mellitus 1.17 (0.68–2.02) 0.577
LA dimension, mm 1.05 (1.01–1.08) 0.016 1.04 (1.01–1.08) 0.025*
Ablation time, minute 1.00 (0.99–1.01) 0.885
Procedure time, minute 1.00 (0.99–1.00) 0.306
LA indicates left atrium; OR, odds ratio.
*P<0.05 in multivariate analysis.
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achievement rates of BDB for linear lines are presented in
Figure 3B.
Discussion
The main ﬁnding of the current study was that patients who
achieved LAPW isolation in AF catheter ablation with a linear
ablation strategy showed better clinical outcomes than those
without LAPW isolation. BDBs of RL or AL did not affect AF/AT
recurrence. At the de novo procedure, the overall BDB rate
for linear ablations was 64.3%, and 74.2% of previously
conﬁrmed BDBs were maintained at the repeat procedure
23.016.1 months after the de novo procedure. The LAPW
isolation rate was 44.7% and was maintained in 62.1% at the
repeat procedure.
Linear Lesion Generation With Catheter Ablation
Linear lesion generation was initially suggested and
attempted in the surgical treatment of AF, and Cox et al
demonstrated the feasibility of curing AF by biatrial linear
lesion generation, with a success rate of 93%.14 Linear
ablation in catheter ablation is derived from the concept
underlying surgical treatment of AF and modiﬁes atrial
substrates and compartmentalizes the atrium into smaller
regions to reduce the critical mass of atrial tissue.15 However,
complete conduction block with transmural lesion generation
remains challenging with catheter ablation, and durability of
conduction block is also an important issue for long-term
successful AF ablation. Even in AF surgery, transmurality of
the lesions is reported to be achievable in only up to 75% of
cases.16 Although Rostock et al reported conduction recovery
in 90% of cases for mitral isthmus line and 79% for RL at the
repeat procedure,17 there are a lack of data on the initial
achievement and durability of BDB rate of linear ablation
lesions. In this study, the overall de novo BDB rate for linear
ablations, including RL, PIL, and AL, was 64.3%, and only
74.2% of previously conﬁrmed BDBs were maintained at
repeat procedure. Although we used a consistent ablation
protocol in this study, the patients in whom BDB can be
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Figure 2. A, Kaplan–Meier analysis of AF/AT recurrence-free rate according to bidirectional block achievement of roof line, (B) posterior-
inferior line (LAPW isolation), (C) anterior line, and (D) the number of lines with bidirectional block among roof line, posterior-inferior line, and
anterior line (0–1 vs 2–3). AF indicates atrial ﬁbrillation; AT, atrial tachycardia; BDB, bidirectional block; LAPW, left atrial posterior wall.
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achieved might be somewhat different from others. Recently,
Kim et al reported a lower reconnection of previously isolated
PV potential in women than in men on the second
procedure.18 It is possible that genetic or intrinsic sex
difference results in a thinner LA myocardial layer in women
than in men.19 Therefore, BDB achievement after linear
ablation can be affected by myocardial wall thickness, lesion
length, or extent of low-voltage scar tissue. In this study, we
found a higher BDB rate of the PIL in females and a smaller LA
dimension on univariate logistic regression analyses. On the
other hand, old age and a larger LA dimension were
independently associated with BDB of the AL, suggesting
that LA with advanced remodeling and ﬁbrosis also con-
tributes to the achievement of BDB.
Clinical Implication of LA Posterior Wall Isolation
In this study, we demonstrated that achievement of LAPW
isolation by additional linear ablations of RL and PIL was
associated with a better clinical outcome. Although Tam-
borero et al20 reported no beneﬁcial effect of LAPW isolation
with linear ablations of RL and PIL, their study group consisted
of 60% paroxysmal AF cases. Like PVs, LAPW embryologically
originates from the cells of the primordial PV21 and thus might
contribute to the initiation of AF with triggered activity22 and
also have a role in perpetuation of AF.23,24 LAPW myocytes
are known to have higher arrhythmogenic potential than other
parts of the LA because of larger intracellular Ca2+ transients,
more sarcoplasmic reticulum calcium content, and less
protein expression of the Na-Ca exchanger,25 as shown in a
representative example of recurred AT in Figure 1B. In this
patient, LAPW isolation was achieved at de novo procedure,
but recurred focal AT originated from LAPW conducted
through the reconnected RL. Moreover, LA size is an
important determinant of AF perpetuation, and therefore LA
mass reduction by LAPW isolation might modify the AF
substrate and have a beneﬁcial effect on the clinical outcome
of catheter ablation—the so-called critical mass hypothesis.26
Various Additional Linear Ablation Strategies
The standard lesion set of additional linear ablation post-CPVI
has not yet been clearly deﬁned. Although the most
commonly added linear lesions are the mitral isthmus and
RL,4,5 some researchers also suggested a lesion set in which
LAPW is isolated by performing RL and PIL.7,27 Furthermore,
the surgical ablation lesion set reported by Edgerton et al,
which is known as the Dallas lesion set, can be generated
successfully with the catheter ablation technique.6,28 In this
study, we performed Dallas lesion set additional linear
ablation with RL and PIL for LAPW isolation in nearly 400
patients with more than 2 years of follow-up. Our results
indicated that although BDB of PIL and consequent LAPW
isolation is difﬁcult to achieve compared to RL or AL, it seems
to be worth the effort.
Ablation Strategies for LA Posterior Wall Isolation
Although several researchers recently suggested the beneﬁcial
effect of LAPW isolation on clinical outcome of PeAF catheter
ablation,29,30 the results are inconsistent20 and the studies
used different ablation strategies for LAPW isolation. Whereas
Table 4. Univariate and Multivariate Cox Regression Analyses of Clinical AF/AT Recurrence After Catheter Ablation
Total Population
Univariate Analysis Multivariate Analysis
HR (95% CI) P Value HR (95% CI) P Value
Male 1.18 (0.77–1.79) 0.452 1.27 (0.68–2.38) 0.461
Age 1.00 (0.99–1.02) 0.663 1.01 (0.99–1.03) 0.505
Body mass index, kg/m2 1.08 (1.01–1.15) 0.025* 1.10 (0.99–1.21) 0.082
Body surface area, m2 2.18 (0.77–6.14) 0.141 0.68 (0.09–5.45) 0.721
Hypertension 1.05 (0.74–1.50) 0.782
Diabetes mellitus 1.15 (0.73–1.81) 0.548
LA dimension, mm 1.01 (0.98–1.04) 0.626 0.99 (0.96–1.02) 0.517
Achievement of BDB
Roof line 0.74 (0.47–1.15) 0.184
Posterior-inferior line (LAPW isolation) 0.65 (0.45–0.93) 0.019* 0.68 (0.47–0.98) 0.041*
Anterior line 0.95 (0.66–1.36) 0.766
Any AF/AT recurrence in the ﬁrst 3 months (blanking period) after catheter ablation was not counted as clinical AF/AT recurrence. AF indicates atrial ﬁbrillation; AT, atrial tachycardia;
BDB, bidirectional block; HR, hazard ratio; LA, left atrium; LAPW, left atrial posterior wall.
*P<0.05.
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our group and others performed additional linear ablation with
RL and PIL for LAPW isolation,20,29 Bai et al conducted LAPW
isolation with extensive ablation of the entire LAPW and
reported an additional beneﬁt over CPVI alone in the PeAF
ablation procedure.30 Furthermore, they veriﬁed CPVI and
LAPW isolation by performing a repeat procedure regardless of
arrhythmia recurrence, and therefore assessed the true impact
of LAPW isolation on clinical outcome.
If complete, LAPW with linear lesions seems to have a
critical mass reduction effect with LA compartmentalization
and fewer ablation lesions with less myocardial injury.
However, BDB of PIL is hard to achieve and there are safety
concerns over collateral damage, including esophagus injury.
Although there were no differences in the major complication
rates and ablation-related complication rates between
patients with LAPW isolation and those without (Table S1),
there was a case of atrioesophageal ﬁstula in each group. The
overall incidence of atrioesophageal ﬁstula was 0.098% (2 of
2047) in the Yonsei AF Ablation cohort. Therefore, further
studies comparing the safety and complications related to
these procedures are warranted. Moreover, incomplete BDB
with gap formation might be rather proarrhythmic. However,
there were no differences in the recurrence types of
tachycardia (AF/AT; Table S2) or AT recurrence rates
(Figure S1) between patients with BDB and those without in
this study, and an extensive LAPW ablation strategy could
result in more myocardial injury and, consequently, might
exhibit arrhythmogenicity.31,32 Further prospective, random-
ized studies with different ablation strategies for LAPW
isolation as endpoints are warranted.
Study Limitations
This study was an observational cohort study from a single
center. Although we conﬁrmed BDB of all linear lesions, some
lesions might have conduction recovery, which may have
affected the clinical outcome. Whether complete LAPW
isolation has a signiﬁcant beneﬁcial effect on clinical outcome
or incomplete BDB has a proarrhythmic effect remain to be
elucidated.
Conclusion
Although BDB of PIL is hard to achieve while avoiding the
esophageal contact area, LAPW isolation is important for a
better clinical outcome in catheter ablation with additional
linear ablation strategy for patients with PeAF.
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Table S1. Anti-arrhythmic drug maintenance and procedure complications according to the 
achievement of left atrial posterior wall isolation. 
Follow-up data 
LAPW isolation (+)  
(n = 178) 
LAPW isolation (–) 
(n = 220) 
p value 
AAD at discharge 35 (19.7%) 60 (27.3%) 0.077 
AAD after blanking period 46 (25.8%) 48 (21.8%) 0.347 
Procedural characteristics 





Complications *10 (5.6%) †6 (2.7%) 0.144 
Major complications 3 (1.7%) 3 (1.3%) 0.794 
‡Ablation-related complications 7 (3.9%) 5 (2.3%) 0.336 
AAD = antiarrhythmic drug 
AAD after blanking period = AAD use before the clinical recurrence or AAD use at last follow-up. 
CFAE = complex fractionated atrial electrogram, CPVI = circumferential pulmonary vein isolation, LAPW = left 
atrial posterior wall. 
*tamponade 2 (1 required open heart surgery), atrio-esophageal (AE) fistula 1, sinus node dysfunction 4, groin 
complication 3. 
†tamponade 2, pleural effusion 1, AE fistula 1, sinus node dysfunction 1, groin complication 1. 
‡groin complications excluded. 




Table S2. Incidence and mode of recurrences depending on the status of BDB of linear 
lesions at de novo procedure and redo mapping. 
De novo procedure (n=398) BDB (+) BDB (-) p value 
Roof line    
Proportion of patients, % 84.7% (337) 15.3% (61)  
Clinical AF/AT recurrence, %  30.0% (101/337) 41.0% (25/61) 0.089 
Proportion of AT recurrence, % 48.5% (49/101) 48.0% (12/25) 0.963 
Posterior-inferior line     
Proportion of patients, % 44.7% (178) 55.3% (220)  
Clinical AF/AT recurrence, %  27.0% (48/178) 35.5% (78/220) 0.070 
Proportion of AT recurrence, % 50.0% (24/48) 47.4% (37/78) 0.780 
Anterior line    
Proportion of patients, % 63.6% (253) 36.4% (145)  
Clinical AF/AT recurrence, %  29.6% (75/253) 35.2% (51/145) 0.254 
Proportion of AT recurrence, % 46.7% (35/75) 51.0% (26/51) 0.634 
Redo mapping (n=52) BDB (+) BDB (-) p value 
Roof line    
Proportion of patients, % 63.5% (33) 36.5% (19)  
Proportion of AT recurrence, % 42.4% (14/33) 47.4% (9/19) 0.730 
Inducible macro-reentrant AT during 
mapping 
15.2% (5/33) 21.1% (4/19) 0.592 
Posterior-inferior line     
Proportion of patients, % 34.6% (18) 65.4% (34)  
Proportion of AT recurrence, % 50.0% (9/18) 41.2% (14/34) 0.542 
Inducible macro-reentrant AT during 
mapping 
16.7% (3/18) 17.6% (6/34) 0.929 
Anterior line    
Proportion of patients, % 40.4% (21) 59.6% (31)  
Proportion of AT recurrence, % 42.9% (9/21) 45.2% (14/31) 0.870 
Inducible macro-reentrant AT during 
mapping 
14.3% (3/21) 19.4% (6/31) 0.635 




Figure S1. Kaplan-Meier analysis of AT (not AF) recurrence-free rate according to BDB 
achievement of roof line (A), posterior-inferior line (LAPW isolation; B), anterior line (C), and 
the number of linear lesions with BDB (0-1 vs. 2-3; D).  BDB = bidirectional block. 
 
 
 
